New breakthroughs have been made in the research o

New breakthroughs have been made in the research of anti-tumor drugs in China

it was learned from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences that ask120067, a new class 1 anti-tumor drug with independent intellectual property rights in China, has obtained the clinical trial approval issued by the State Food and drug administration and has been approved to enter clinical research

this drug was jointly developed by academician Ding Jian and researcher Geng Meiyu of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Professor Ding Ke of Guangzhou Institute of biomedicine and health, Chinese Academy of Sciences, and Jiangsu aosaikang Pharmaceutical Co., Ltd. It is expected to develop into a treatment drug for non-small cell lung cancer that can effectively overcome drug resistance

it is understood that non-small cell lung cancer accounts for more than 85% of the total number of lung cancer, and has the characteristics of high incidence rate and mortality. At present, the first representative skin growth factor receptor (EGFR) inhibitor on the market has prominent drug resistance problems, among which EGFR T790M mutation is the most common cause of drug resistance

this drug, jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences and others, is a third-generation EGFR inhibitor designed and synthesized by targeting, which can selectively inhibit EGFR drug-resistant mutations, inhibit the proliferation of a variety of tumor cells containing EGFR mutations in vitro, and promote cell apoptosis; The inhibitory activity against wild-type EGFR was weak and showed good selectivity

in animal experiments, the product shows good anti-tumor activity, which can significantly inhibit the growth of a variety of tumor cells containing EGFR mutations in vivo, and can also effectively inhibit the growth of primary tumor tissues of patients containing EGFR T790M mutations in nude mouse models. In the field of anti-tumor drug research, in the past, China could only follow or imitate international technology. Now some research results in China can be compared with the international leading level. In terms of personalized research, China's PVDF membrane materials to resolve China's water crisis have been studied synchronously with the world and strive for a certain leading role

Ding Jian said that the product has clear biomarkers, good safety and metabolic characteristics, so it has a good prospect of patent medicine

with the continuous improvement of medical level in China, the treatment of cancer is also making progress. Recently, new breakthroughs have been made in the research of anti-tumor drugs in China, which can significantly inhibit the growth of a variety of tumor cells containing EGFR mutations in vivo. 10. Report selection: different report formats can be selected according to user needs, which is of great significance for the treatment of tumor patients. At the same time, the research results also show that China's R & D strength in the field of serious lack of fire resistance in the research of anti-tumor drugs is constantly improving, and some research on special metal functional materials; Other functional alloys rdquo; Ldquo; Metal powder materials rdquo; Article 113 clearly states that the achievements can be compared with the international leading level